Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of spinal muscular atrophy (SMA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal (IVT) pharmacotherapy approvals across different drug…
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…
Clarivate Epidemiology’s coverage of genitourinary syndrome of menopause (GSM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…
Clarivate Epidemiology’s coverage of ischemic stroke (IS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of sepsis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Clarivate Epidemiology’s coverage of herpes zoster (HZ) comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets. We report the incidence of HZ for each…
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…